Economic damage of pneumococcal vaccination absence as a risk factor for complications of chronic obstructive pulmonary disease
- Authors: Orlova E.A.1, Dorfman I.P.1, Umerova A.R.1,2, Kantemirova B.I.1, Orlov M.A.1, Abdullaev M.A.1
-
Affiliations:
- Astrakhan State Medical University
- Territorial body of Federal State Surveillance Service in Healthcare for Astrakhan Region
- Issue: Vol 10, No 2 (2022)
- Pages: 187-197
- Section: Articles
- URL: https://journals.rcsi.science/2307-9266/article/view/111738
- DOI: https://doi.org/10.19163/2307-9266-2022-10-2-187-197
- ID: 111738
Cite item
Abstract
The aim of the article is the evaluation of the economic damage (ED) because of the absence of pneumococcal vaccination as a leading risk factor for the development of community-acquired pneumonia (CAP) and acute exacerbations of а chronic obstructive pulmonary disease (COPD).
Materials and methods. The method of attributive statistics was used for the first time to assess the ED of the vaccination absence as an independent risk factor contributing to the development of CAP and COPD exacerbations in the Astrakhan region for the period of 2015–2019. To do this, at the beginning of the study based on the literature data, a relative risk of COPD complications associated with the absence of pneumococcal vaccination was determined. Using it as a risk factor, prevalence rates (a proportion of non-vaccinated patients with COPD), the population attributable risk (PAR) was calculated. Further, the annual economic damage (ED) from the development of CAP and COPD exacerbations was determined. To assess the cost-effectiveness of the COPD complications prevention, vaccination costs of newly registered patients were calculated and the ratio of these costs to the average annual ED was determined.
Results. A decrease in the non-vaccinated patients’ proportion corresponds to the decrease in the total ED from COPD complications: from 13.16 million rubles to 6.06 million rubles during the observation period. The calculations showed that due to the increase in the vaccinated patients’ proportion over a five-year observation period, the ED from the CAP development decreased by 2.1 times, from exacerbations of COPD – by 2.3 times. The vaccination costs of newly diagnosed COPD cases amounted to 0.63 million rubles. Thus, to prevent the annual ED of 3.24 million rubles, the sum for the state to spend, should be 5.2 times as small.
Conclusion. A study on the evaluation of the ED due to the risk factor (RF), the pneumococcal vaccination absence, showed that its elimination reduces the risk of acute COPD exacerbations and the development of CAP, as well the ED, as associated with them. Reducing the economic costs of the health care system with significantly lower vaccination costs, makes this preventive measure economically viable.
Full Text
##article.viewOnOriginalSite##About the authors
Ekaterina A. Orlova
Astrakhan State Medical University
Author for correspondence.
Email: eorlova56@mail.ru
ORCID iD: 0000-0001-7169-3586
Candidate of Sciences (Medicine), Associate Professor, Head of the Department of Pharmacology
Russian Federation, 121, Str. Bakinskaya, Astrakhan, 414000Inna P. Dorfman
Astrakhan State Medical University
Email: inna1977@inbox.ru
ORCID iD: 0000-0003-1561-0592
Candidate of Sciences (Medicine), Associate Professor, Associate Professor of the Department of Clinical Pharmacology
Russian Federation, 121, Str. Bakinskaya, Astrakhan, 414000Adela R. Umerova
Astrakhan State Medical University; Territorial body of Federal State Surveillance Service in Healthcare for Astrakhan Region
Email: adelya_umerova@mail.ru
ORCID iD: 0000-0002-3129-2443
Doctor of Sciences (Medicine), Associate Professor, Head of the Department of Clinical Pharmacology, Head
Russian Federation, 121, Str. Bakinskaya, Astrakhan, 414000; 27, Kommunisticheskaya Str., Astrakhan, 414040Bela I. Kantemirova
Astrakhan State Medical University
Email: belakantemirova@rambler.ru
ORCID iD: 0000-0003-3278-2556
Doctor of Sciences (Medicine), Associate Professor, Professor of the Department of Pharmacology
Russian Federation, 121, Str. Bakinskaya, Astrakhan, 414000Mikhail A. Orlov
Astrakhan State Medical University
Email: orlovdoc56@gmail.com
ORCID iD: 0000-0002-8995-6572
Doctor of Sciences (Medicine), Professor, Head of the Department of Medical Rehabilitation
Russian Federation, 121, Str. Bakinskaya, Astrakhan, 414000Musalitdin A. Abdullaev
Astrakhan State Medical University
Email: abdullaev-musalitdin@mail.ru
ORCID iD: 0000-0001-7374-2660
post-graduate student of the Department of Pharmacology
Russian Federation, 121, Str. Bakinskaya, Astrakhan, 414000